| Dr Derek Miles, MD | |
|
907 E Sunflower Rd, Suite 103, Cleveland, MS 38732-2830 | |
| (662) 846-9990 | |
| (662) 846-5444 |
| Full Name | Dr Derek Miles |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 30 Years |
| Location | 907 E Sunflower Rd, Cleveland, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407887391 | NPI | - | NPPES |
| 09016081 | Medicaid | MS | |
| 0126078 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 17441 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bolivar Medical Center | Cleveland, MS | Hospital |
| Northwest Mississippi Medical Center | Clarksdale, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bolivar Physician Practices Llc | 6305995895 | 16 |
News Archive
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B/2 dose-ranging clinical study with PMX-60056, a synthetic small-molecule designed to reverse heparin and low molecular weight heparin anticoagulants.
Myriad Genetics has announced that it has been awarded a five-year, $14.2 million contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced it submitted a supplemental New Drug Application with the U.S. Food and Drug Administration (FDA) for a Ready-to-Use formulation of FUSILEV (levoleucovorin) for Injection.
Blocking a key molecule protects breast implants, permanent catheters, pacemakers, artificial joints, glucose sensors for diabetics, and other biomaterials from rejection and damage by the body, according to a study published this month in The American Journal of Pathology.
› Verified 1 days ago
| Entity Name | Bolivar Physician Practices Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063659530 PECOS PAC ID: 6305995895 Enrollment ID: O20090512000274 |
News Archive
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B/2 dose-ranging clinical study with PMX-60056, a synthetic small-molecule designed to reverse heparin and low molecular weight heparin anticoagulants.
Myriad Genetics has announced that it has been awarded a five-year, $14.2 million contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced it submitted a supplemental New Drug Application with the U.S. Food and Drug Administration (FDA) for a Ready-to-Use formulation of FUSILEV (levoleucovorin) for Injection.
Blocking a key molecule protects breast implants, permanent catheters, pacemakers, artificial joints, glucose sensors for diabetics, and other biomaterials from rejection and damage by the body, according to a study published this month in The American Journal of Pathology.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Derek Miles, MD 907 E Sunflower Rd, Suite 103, Cleveland, MS 38732-2830 Ph: (662) 846-9990 | Dr Derek Miles, MD 907 E Sunflower Rd, Suite 103, Cleveland, MS 38732-2830 Ph: (662) 846-9990 |
News Archive
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B/2 dose-ranging clinical study with PMX-60056, a synthetic small-molecule designed to reverse heparin and low molecular weight heparin anticoagulants.
Myriad Genetics has announced that it has been awarded a five-year, $14.2 million contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced it submitted a supplemental New Drug Application with the U.S. Food and Drug Administration (FDA) for a Ready-to-Use formulation of FUSILEV (levoleucovorin) for Injection.
Blocking a key molecule protects breast implants, permanent catheters, pacemakers, artificial joints, glucose sensors for diabetics, and other biomaterials from rejection and damage by the body, according to a study published this month in The American Journal of Pathology.
› Verified 1 days ago